An institutional investor in the healthcare field is exercising options to purchase 5 million shares of a company
Yes Fight Biopharma
-1.32%
Base:22.8
opening:22.5
Tall:0
low:0
change:—
Page Quote News Graphs Company Profile Recommendations
More articles on the subject:
In the amount of $ 10 million, at an exercise price of $ 2 per share (below yesterday’s closing price of $ 2.15, at the same price as the share price in August this year, the date of the options issue.
According to Fayette, it will use the net proceeds from the working capital offering including the launch of Phase II research in NASH and Phase III research for liver cancer as well as for other general purposes.
Yes Yes Fate reported that all malignant lesions in a liver cancer patient who participated in a Phase 2 trial of the Namodenoson drug developed by the company have disappeared. In treatment with Namodenoson. The patient survived five years, during which the clinical benefits of treatment included disappearance of the malignant lesions, normal liver function, disappearance of peritoneal carcinomatosis leading to complete cessation of all cancerous lesions.
The company’s share jumped 70% yesterday to a price of $ 2.15 per share, and a market value of $ 43 million, compared to a price of $ 1.27 per share and a market value of $ 25.5 million. Last night in Tel Aviv, the stock jumped in Tel Aviv at a price of NIS 0.13, and recorded an annual decline of 37%.
Annual chart of the stock
Comments on the article(0):
Your response has been received and will be published subject to system policies.
Thanks.
For a new response
Your response was not sent due to a communication problem, please try again.
Return to comment
.